What Are SGLT2 Inhibitors?

SGLT2 inhibitors, also known as gliflozins, represent a modern class of oral medications for managing type 2 diabetes. Approved by the FDA starting in 2013, these drugs include canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro). They are typically prescribed as monotherapy or in combination with other diabetes agents like metformin or insulin. Unlike older medications that stimulate insulin secretion, SGLT2 inhibitors work independently of insulin by targeting the kidneys.

How SGLT2 Inhibitors Work

The kidneys filter about 180 grams of glucose daily under normal conditions. Nearly all of this glucose is reabsorbed into the bloodstream by transporter proteins, especially the sodium-glucose co-transporter 2 (SGLT2) located in the proximal tubule. SGLT2 inhibitors block this protein, preventing glucose reabsorption and shunting excess sugar into the urine. This lowers blood glucose levels without requiring the pancreas to release more insulin. The effect is glucose-dependent, meaning the risk of hypoglycemia is low when used alone, though it can occur when combined with insulin or sulfonylureas.

Because the drug’s mechanism does not depend on beta-cell function, it remains effective even as type 2 diabetes progresses. Additionally, the osmotic diuresis caused by glucose excretion contributes to modest reductions in blood pressure and slight weight loss. Over time, these effects translate into meaningful cardiorenal benefits, as shown in major outcome trials.

Benefits of SGLT2 Inhibitors

Glycemic Control

Clinical studies demonstrate that SGLT2 inhibitors reduce HbA1c by approximately 0.5% to 1.0% when used as add-on therapy. The reduction is sustained over years, with no evidence of secondary failure in most patients. The effect is additive to other drug classes, making them useful for patients who need additional glucose lowering despite metformin or insulin.

Weight Loss

Because SGLT2 inhibitors cause up to 60–100 grams of glucose to be lost in urine each day (equivalent to 240–400 calories), patients typically lose 2–4 kg (4–9 lbs) over six months. Weight reduction is gradual and stabilizes after several months. This makes gliflozins especially attractive for overweight or obese individuals with type 2 diabetes.

Blood Pressure Reduction

The osmotic diuresis and natriuresis induced by SGLT2 inhibition lower systolic blood pressure by 3–5 mmHg and diastolic by 1–2 mmHg. Unlike thiazide diuretics, this effect does not trigger compensatory sympathetic activation or significant metabolic disturbances, improving cardiovascular risk profiles.

Cardiovascular Protection

Large FDA-mandated outcomes trials—such as EMPA-REG OUTCOME for empagliflozin, CANVAS for canagliflozin, and DECLARE-TIMI 58 for dapagliflozin—have shown significant reductions in major adverse cardiovascular events (MACE), hospitalization for heart failure, and cardiovascular death. Empagliflozin, in particular, reduced the risk of cardiovascular death by 38% in patients with established cardiovascular disease. These benefits have led to updated guidelines recommending SGLT2 inhibitors in patients with type 2 diabetes and atherosclerotic cardiovascular disease or heart failure.

Renal Protection

Beyond cardiovascular benefits, SGLT2 inhibitors slow the progression of diabetic kidney disease. The CREDENCE trial demonstrated that canagliflozin reduced the risk of end-stage kidney disease, doubling of serum creatinine, or renal death by 34% in patients with albuminuric chronic kidney disease. Dapagliflozin confirmed these findings in the DAPA-CKD trial, showing benefit even in patients without diabetes. As a result, gliflozins are now considered foundational therapy for heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease.

Potential Side Effects and Risks

While SGLT2 inhibitors are generally well tolerated, they carry specific adverse effects that new patients must understand.

Common Side Effects

  • Genitourinary infections: Because glucose in urine promotes bacterial and fungal growth, women have a higher risk of urinary tract infections (UTIs) and genital yeast infections. Men may develop balanitis. Good hygiene and prompt treatment of infections reduce complications.
  • Dehydration and hypotension: The diuretic effect can cause volume depletion, especially in older adults, those taking loop diuretics, or patients with low oral intake. Symptoms include dizziness, dry mouth, and orthostatic hypotension.
  • Increased urination: Polyuria and nocturia are expected during the first weeks but usually lessen over time.

Serious Adverse Events

  • Diabetic ketoacidosis (DKA): Rare but dangerous, euglycemic DKA (blood glucose <250 mg/dL) can occur without marked hyperglycemia. Triggers include acute illness, surgery, starvation, alcohol, and insulin dose reduction. Patients should know the symptoms: nausea, vomiting, abdominal pain, confusion, and fatigue. Immediate medical attention is required.
  • Lower limb amputations: The CANVAS program found an increased risk of toe and foot amputations with canagliflozin. The FDA added a black box warning for this drug. The mechanism is unclear but may involve altered wound healing. Patients with prior amputation, peripheral artery disease, or neuropathy should discuss alternative options.
  • Acute kidney injury: Although rare, acute interstitial nephritis and acute tubular necrosis have been reported. The drugs are contraindicated in patients with eGFR below 30 mL/min/1.73 m² (except for dapagliflozin, which can be used down to 25 mL/min/1.73 m² for renal endpoints). Renal function must be monitored before and during therapy.
  • Fournier’s gangrene: Necrotizing fasciitis of the perineum is an extremely rare but life-threatening infection requiring immediate surgical debridement and antibiotics. Patients should seek urgent care if they experience genital pain, swelling, fever, or malaise.

Drug Interactions

SGLT2 inhibitors may interact with diuretics (additive volume depletion), insulin or sulfonylureas (increased hypoglycemia risk), and drugs that affect renal function (e.g., NSAIDs, ACE inhibitors). Dose adjustments or additional monitoring may be necessary.

Who Should Consider SGLT2 Inhibitors?

Current American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend SGLT2 inhibitors as part of first-line or second-line therapy in specific populations:

  • Established cardiovascular disease (CVD) or high risk: Empagliflozin or canagliflozin are preferred to reduce MACE and heart failure hospitalization.
  • Heart failure with reduced ejection fraction (HFrEF): Dapagliflozin and empagliflozin have shown robust benefits regardless of diabetes status.
  • Chronic kidney disease (eGFR 25–60 mL/min/1.73 m²) with albuminuria: Dapagliflozin or canagliflozin slow progression.
  • Overweight or obesity combined with inadequate glycemic control: Weight loss and insulin-independent glucose lowering make gliflozins attractive.
  • Intolerance to metformin or need for additional glucose lowering without weight gain.

However, SGLT2 inhibitors are not suitable for everyone. Contraindications include type 1 diabetes (except for off-label use of dapagliflozin in some countries), eGFR below 25–30 mL/min (depending on the drug), history of severe hepatic impairment, pregnancy or lactation, and history of ketoacidosis or foot ulcers. Patients with recurrent UTIs or genital infections should weigh risks carefully.

How to Take SGLT2 Inhibitors

All gliflozins are taken once daily by mouth, typically before the first meal of the day. Dosing varies by drug and renal function:

  • Canagliflozin: 100 mg or 300 mg once daily
  • Dapagliflozin: 5 mg or 10 mg once daily
  • Empagliflozin: 10 mg or 25 mg once daily
  • Ertugliflozin: 5 mg or 15 mg once daily

Starting doses should be lower in patients with renal impairment (eGFR 30–60). Patients should stay well hydrated and avoid skipping meals, especially if also using insulin. Blood glucose monitoring is important initially, though frequent testing is not required once the dose is stable. Annual vaccinations (influenza, pneumococcal, COVID-19) and podiatry examinations are recommended to reduce infection and amputation risks.

Monitoring and Follow-Up

Before starting therapy, obtain baseline renal function (eGFR, creatinine), hemoglobin A1c, and blood pressure. Check for history of recurrent infections or amputation. Initiate at the lowest effective dose and reassess after 4–8 weeks. Follow-up should include:

  • eGFR and electrolytes every 3–6 months
  • Signs of volume depletion, especially in warm weather or during illness
  • Foot inspection for ulcers or wounds
  • Urine dipstick or culture if symptoms of UTI develop
  • Lipid panel (modest LDL-C increase may occur, though remains controversial)

If the patient experiences nausea, vomiting, or abdominal pain with acidosis, check serum ketones even if blood glucose is normal. Interrupt therapy during acute illness, major surgery, or prolonged fasting. Resumption should be discussed with the healthcare team once the patient is metabolically stable.

Lifestyle Considerations

While SGLT2 inhibitors offer pharmacological benefits, they work best alongside lifestyle modifications. Patients should adopt a heart-healthy diet, engage in at least 150 minutes of moderate-intensity exercise per week, and maintain adequate fluid intake (8–10 glasses of water daily). Because glucose loss in urine increases osmotic diuresis, alcohol consumption should be limited to avoid dehydration and ketone production. Smoking cessation and foot care are especially important for patients at risk of amputation. Patients should also be educated about the “sick day rules”: stop the drug, increase fluid intake, check blood glucose and ketones, and consult their doctor if symptoms persist.

Comparing SGLT2 Inhibitors to Other Diabetes Medications

Unlike sulfonylureas or insulin, SGLT2 inhibitors do not cause weight gain and carry a low hypoglycemia risk. They differ from GLP-1 receptor agonists (such as semaglutide or liraglutide) in that gliflozins have a stronger diuretic effect and proven benefits in heart failure, while GLP-1 agonists offer more weight loss and reduction in atherosclerotic events. Both drug classes are often used together for additive glucose lowering and complementary cardiovascular benefits.

Cost and Insurance Coverage

SGLT2 inhibitors are generally more expensive than metformin or sulfonylureas, but many insurance plans cover them. Generic versions of canagliflozin and dapagliflozin are now available in some regions. Patient assistance programs from manufacturers can reduce out-of-pocket costs. Before filling a prescription, check your formulary and prior authorization requirements.

Frequently Asked Questions for New Patients

Will I need to check my blood sugar more often?

Initially, yes. Once your dose is stable and you are not on insulin or sulfonylureas, less frequent testing may suffice. However, periodic monitoring helps assess efficacy and detect hypoglycemia.

What should I do if I have a genital infection?

Contact your doctor. Over-the-counter antifungal creams often work for yeast infections, but UTIs may require antibiotics. Do not stop the medication without consulting your provider, as the benefits usually outweigh the temporary discomfort.

Can I take SGLT2 inhibitors if I have type 1 diabetes?

No. SGLT2 inhibitors are not approved for type 1 diabetes due to the high risk of ketoacidosis. Off-label use is only considered in select expert centers.

Will I lose weight on these drugs?

Most patients lose modest weight (2–4 kg) over six months, but the amount varies. The effect plateaus, and weight loss is less than with GLP-1 agonists. Combining with diet and exercise enhances results.

Are there any natural supplements that work like SGLT2 inhibitors?

No. No supplement reliably blocks SGLT2. Claims about “natural” alternatives are unproven and potentially dangerous. Stick to proven pharmacotherapy.

Conclusion

SGLT2 inhibitors have transformed the treatment of type 2 diabetes by offering effective glucose control along with substantial cardiovascular and renal protection. For new patients, understanding how these drugs work, their benefits and risks, and the necessary monitoring steps can lead to better outcomes and fewer complications. As with any medication, shared decision-making with a healthcare provider is essential. Review the latest treatment guidelines from the American Diabetes Association and the National Kidney Foundation, and consult your doctor to see if an SGLT2 inhibitor is right for you. Additional information on drug-specific side effects is available through the FDA Drug Information Portal and PubMed.